FDA Arthritis Drugs Advisory Committee
Executive Summary
Will discuss "NDA Day" procedures and objectives and the role of the committee in the review of Rx Jan. 27-28 meeting. In June, the arthritis committee participated in the review of Syntex/Procter & Gamble's naproxen sodium OTC switch application and recommended against approval. A review of Greenwich Pharmaceuticals Therafectin, which was rejected by FDA in November, is set for Jan. 27. The meeting takes place in conference rooms D&E of FDA's Parklawn building beginning at 8:30 a.m. each day
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth